Skip to main content
Erschienen in: International Urology and Nephrology 5/2018

13.03.2018 | Urology - Original Paper

Does sex matter? A matched pairs analysis of neuromodulation outcomes in women and men

verfasst von: Laura N. Nguyen, Jamie Bartley, Kim A. Killinger, Priyanka Gupta, John Lavin, Ayad Khourdaji, Jason Gilleran, Natalie Gaines, Judith A. Boura, Kenneth M. Peters

Erschienen in: International Urology and Nephrology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Aims

To evaluate whether baseline symptoms and outcomes are influenced by gender in a matched cohort undergoing neuromodulation.

Methods

Patients in our prospective neuromodulation database that had a tined lead placed were reviewed. Those that had implantable pulse generator (IPG) placed were matched on age and urologic diagnosis. History, voiding diaries, satisfaction, Interstitial Cystitis Symptom/Problem Index (ICSIPI), and overactive bladder symptom severity (OABq ss)/health-related quality of life (HRQOL) preimplant and over 3 years were evaluated using descriptive statistics, repeated measures, and matched pair GEE or mixed analyses.

Results

Of 590 patients in the database, more women than men received an IPG (450/488; 92.2 vs. 84/102; 82.4%; p = 0.0011). Eighty matched pairs (n = 160; 81% ≥ 50 years old; 56.25% had urgency/frequency with urge incontinence—UI) were identified and evaluated. On voiding diaries, volume/void was greater in women only at baseline (p = 0.040); both groups improved over time (p < 0.0001). Urinary frequency improved in both women and men (p = 0.0010; p = 0.0025). Over 3 years, UI episodes/day improved only in men (p = 0.017) and UI severity improved only in women (p < 0.0001). ICSIPI, OABq ss, and HRQOL scores improved similarly in both groups (p < 0.0001 for all measures in both groups), and although more women were satisfied at 3 months (p = 0.027), groups did not differ at other time points.

Conclusions

More women undergo neuromodulation and have initial success and subsequent IPG implantation. UI episodes improved only in men, and UI severity improved only in women. Both women and men experienced similar levels of symptom improvement on other measures.
Literatur
1.
Zurück zum Zitat Irwin DE, Milsom I, Hunskaar S et al (2006) Population based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315CrossRefPubMed Irwin DE, Milsom I, Hunskaar S et al (2006) Population based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315CrossRefPubMed
2.
Zurück zum Zitat Steward WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. Worl J Urol 20:327–336 Steward WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. Worl J Urol 20:327–336
3.
Zurück zum Zitat Laudano MA, Seklehner S, Sandhu J, Reynolds WS, Garrett KA, Milsom JW, Lee RK (2015) Disparities in the use of sacral neuromodulation among medicare beneficiaries. J Urol 194:449–453CrossRefPubMed Laudano MA, Seklehner S, Sandhu J, Reynolds WS, Garrett KA, Milsom JW, Lee RK (2015) Disparities in the use of sacral neuromodulation among medicare beneficiaries. J Urol 194:449–453CrossRefPubMed
4.
Zurück zum Zitat Cameron AP, Anger JT, Madison R, Saigal CS, Clemens JQ (2011) National trends in the usage and success of sacral nerve test stimulation. J Urol 185:970–975CrossRefPubMedPubMedCentral Cameron AP, Anger JT, Madison R, Saigal CS, Clemens JQ (2011) National trends in the usage and success of sacral nerve test stimulation. J Urol 185:970–975CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Anger JT, Cameron AP, Madison R, Saigal C, Clemens JQ (2016) Outcomes of sacral neuromodulation in a privately insured population. Neuromodulation 19(7):780–784CrossRefPubMedPubMedCentral Anger JT, Cameron AP, Madison R, Saigal C, Clemens JQ (2016) Outcomes of sacral neuromodulation in a privately insured population. Neuromodulation 19(7):780–784CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Anger JT, Cameron AP, Madison R, Saigal C, Clemens JQ (2013) Predictors of implantable pulse generator placement after sacral neuromodulation: Who does better? Neuromodul Technol Neural Interface 17:381–384CrossRef Anger JT, Cameron AP, Madison R, Saigal C, Clemens JQ (2013) Predictors of implantable pulse generator placement after sacral neuromodulation: Who does better? Neuromodul Technol Neural Interface 17:381–384CrossRef
7.
Zurück zum Zitat Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological Association; Society of Urodynamics, Female Pelvic Medicine (2015) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 193(5):1572–1580 (Epub 2015 Jan 23)CrossRefPubMed Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological Association; Society of Urodynamics, Female Pelvic Medicine (2015) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 193(5):1572–1580 (Epub 2015 Jan 23)CrossRefPubMed
8.
Zurück zum Zitat Peters KM, Killinger KA, Boguslawski BM, Boura JA (2010) Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn 29:1267–1271CrossRefPubMed Peters KM, Killinger KA, Boguslawski BM, Boura JA (2010) Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn 29:1267–1271CrossRefPubMed
9.
Zurück zum Zitat Bartley J, Gilleran J, Peters K (2013) Neuromodulation for overactive bladder. Nat Rev Urol 10(9):513–521CrossRefPubMed Bartley J, Gilleran J, Peters K (2013) Neuromodulation for overactive bladder. Nat Rev Urol 10(9):513–521CrossRefPubMed
10.
Zurück zum Zitat Jiang YH, Kuo HC (2017) Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder. Neurourol Urodyn 36(2):338–343CrossRefPubMed Jiang YH, Kuo HC (2017) Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder. Neurourol Urodyn 36(2):338–343CrossRefPubMed
11.
Zurück zum Zitat Abrams P, Artibani W, Gajewski J, Hussain I (2006) Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 68(2):17–28CrossRefPubMed Abrams P, Artibani W, Gajewski J, Hussain I (2006) Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 68(2):17–28CrossRefPubMed
12.
13.
Zurück zum Zitat Stav K, Dwyer PL, Rosamilia A (2009) Women overestimate daytime urinary frequency: the importance of the bladder diary. J Urol 181:2176–2180CrossRefPubMed Stav K, Dwyer PL, Rosamilia A (2009) Women overestimate daytime urinary frequency: the importance of the bladder diary. J Urol 181:2176–2180CrossRefPubMed
14.
Zurück zum Zitat Patra PB, Patra S (2012) Sex differences in the physiology and pharmacology of the lower urinary tract. Curr Urol 6:179–188CrossRef Patra PB, Patra S (2012) Sex differences in the physiology and pharmacology of the lower urinary tract. Curr Urol 6:179–188CrossRef
15.
Zurück zum Zitat Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J (2004) Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry 75(4):637–639CrossRefPubMedPubMedCentral Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J (2004) Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry 75(4):637–639CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Jousilahti P, Vartiainen E, Tuomilehto J, Puska P (1999) Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14,786 middle-aged men and women in Finland. Circulation 99(9):1165–1172CrossRefPubMed Jousilahti P, Vartiainen E, Tuomilehto J, Puska P (1999) Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14,786 middle-aged men and women in Finland. Circulation 99(9):1165–1172CrossRefPubMed
17.
Zurück zum Zitat Sielatycki JA, Parker SL, Godil SS, McGirt MJ, Devin CJ (2015) Do patient demographics and patient-reported outcomes predict 12-month loss to follow-up after spine surgery? Spine 40(24):1934–1940CrossRefPubMed Sielatycki JA, Parker SL, Godil SS, McGirt MJ, Devin CJ (2015) Do patient demographics and patient-reported outcomes predict 12-month loss to follow-up after spine surgery? Spine 40(24):1934–1940CrossRefPubMed
18.
Zurück zum Zitat Berheto TM, Haile DB, Mohammed S (2014) Predictors of loss to follow-up in patients living with HIV/AIDS after initiation of antiretroviral therapy. N Am J Med Sci. 6(9):453–459CrossRefPubMedPubMedCentral Berheto TM, Haile DB, Mohammed S (2014) Predictors of loss to follow-up in patients living with HIV/AIDS after initiation of antiretroviral therapy. N Am J Med Sci. 6(9):453–459CrossRefPubMedPubMedCentral
Metadaten
Titel
Does sex matter? A matched pairs analysis of neuromodulation outcomes in women and men
verfasst von
Laura N. Nguyen
Jamie Bartley
Kim A. Killinger
Priyanka Gupta
John Lavin
Ayad Khourdaji
Jason Gilleran
Natalie Gaines
Judith A. Boura
Kenneth M. Peters
Publikationsdatum
13.03.2018
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 5/2018
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-018-1843-8

Weitere Artikel der Ausgabe 5/2018

International Urology and Nephrology 5/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.